GET DAILY SIGNALSSimulations Plus (SLP) Readies Fiscal Q4 2026 Earnings Report
Key Takeaways
- Simulations Plus, Inc. (SLP), a provider of modeling and simulation software for drug development, is expected to report fiscal fourth quarter 2026 results (for the quarter ended August 31, 2026) after the market closes on Thursday, October 29, 2026.
- Wall Street consensus calls for earnings per share (EPS) of $0.09 on revenue of approximately $17.44 million, according to market estimates.
- The comparison is challenging: in the same quarter a year earlier, the company posted EPS of $0.10 on revenue of $17.46 million.
- Simulations Plus has beaten consensus EPS estimates in six of its last eight quarters, most recently reporting $0.30 per share in fiscal Q3 2026 against a $0.23 estimate.
- Management's fiscal 2026 guidance calls for EPS of $0.75 to $0.85 and revenue of $79 million to $82 million.
Earnings Context and Why It Matters
Simulations Plus closes out a fiscal year that has featured strong mid-year momentum and a mixed start. The company develops software used by pharmaceutical and biotechnology companies to model and simulate drug behavior, helping clients streamline research and development and regulatory submissions. Its fiscal fourth quarter often carries seasonal weight as contracts and renewals land before the August 31 year-end. Investors will be watching whether the company can sustain the revenue strength seen in recent quarters while managing the softer growth implied by consensus estimates for the period. The results will also frame how management enters fiscal 2027, making this report a meaningful barometer for both near-term execution and longer-term demand across the life sciences software market. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
Analysts expect Simulations Plus to report EPS of $0.09 on revenue of roughly $17.44 million for the fiscal fourth quarter of 2026. That would represent a modest year-over-year decline from the prior-year quarter, when the company delivered EPS of $0.10 on revenue of $17.46 million. For context, the company reported fiscal Q3 2026 EPS of $0.30 on revenue of approximately $21.89 million, comfortably ahead of the $0.23 consensus EPS estimate. Management's full-year fiscal 2026 outlook projects EPS of $0.75 to $0.85 and revenue of $79 million to $82 million, so the fourth-quarter result will help determine whether the company lands within that guided range. Investors are likely to focus on software revenue growth, services mix, and any update to the company's forward outlook. From what I see, the year-over-year comparison here is worth monitoring closely.
Market Reaction and Investor Sentiment
Sentiment heading into the report is measured, reflecting the soft year-over-year comparison embedded in consensus estimates. Simulations Plus has a track record of delivering earnings surprises, exceeding EPS expectations in six of its last eight quarters, which may temper bearish positioning. However, the fiscal fourth quarter has occasionally produced in-line or modest results given the seasonality of the business. Key risk factors include the timing of large software contracts, potential shifts in customer research and development budgets, and any foreign-exchange or acquisition-related effects. Investors will also parse management's commentary on the demand environment for biosimulation and cheminformatics software as a signal for the coming fiscal year. One thing that stands out is the company's history of beats, which could influence how the market digests any shortfall.
Forward Outlook and Key Factors to Monitor
Following the earnings report, investors will want to watch several forward-looking signals. First, any update to guidance for fiscal 2027 will be closely read, as it sets the baseline for growth expectations over the next twelve months.
Second, the trajectory of software revenue versus services revenue matters. Software, particularly subscription-based offerings, is generally viewed as higher quality and more recurring, so the mix between these segments can influence how the market values the results.
Third, keep an eye on operating margins and expense trends. Continued investment in research and development and in the company's expanding product portfolio could pressure near-term profitability even as it supports longer-term growth.
Finally, broader industry dynamics in pharmaceutical research and development spending, as well as any commentary on client renewal activity, will help investors assess whether demand remains resilient. While these factors will not resolve in a single quarter, they collectively shape the outlook for Simulations Plus heading into fiscal 2027.
Using Tickeron’s AI Tools in My Research
I often turn to Tickeron’s AI Screener when preparing for earnings like this one. The tool lets me quickly filter stocks by fundamentals, technical patterns, and AI signals, helping me compare SLP against peers in the life sciences software space. It has become a regular part of how I narrow down ideas and check context before reports like this hit the wire. In my view, it adds a structured layer to the analysis without replacing the need to review the actual numbers and guidance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for SLP turns positive, indicating new upward trend
SLP saw its Momentum Indicator move above the 0 level on September 23, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned positive. In 62 of the 88 cases, the stock moved higher in the following days. The odds of a move higher are at 70%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +0.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLP advanced for three days, in 214 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 87 of 189 cases where SLP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 46%.
Bearish Trend Analysis
The 10-day RSI Indicator for SLP moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In 24 of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 17 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Moving Average Convergence Divergence Histogram (MACD) for SLP turned negative on October 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 36 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.
SLP broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 41 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. SLP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.691) is normal, around the industry mean (4.353). P/E Ratio (45.122) is within average values for comparable stocks, (13.253). SLP's Projected Growth (PEG Ratio) (9.885) is very high in comparison to the industry average of (2.133). Dividend Yield (0.013) settles around the average of (0.012) among similar stocks. P/S Ratio (4.539) is also within normal values, averaging (6.065).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of software for use in pharmaceutical research
Industry ServicestotheHealthIndustry
Advertisement